Cover Image
市場調查報告書

SK Biopharmaceuticals Co., Ltd. :產品平台分析

SK Biopharmaceuticals Co., Ltd. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 251723
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
SK Biopharmaceuticals Co., Ltd. :產品平台分析 SK Biopharmaceuticals Co., Ltd. - Product Pipeline Review - 2016
出版日期: 2016年03月31日 內容資訊: 英文 49 Pages
簡介

SK Biopharmaceuticals Co., Ltd.,是開發中樞神經系統疾病新的治療藥的製藥公司,其產品主要用於癲癇、不安神經症、憂鬱症、思覺失調症、帕金森氏症、大腸躁鬱症、糖尿病等治療。

本報告提供SK Biopharmaceuticals Co., Ltd.的治療藥開發平台的現狀及各開發階段比較分析,各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

SK Biopharmaceuticals Co., Ltd.的基本資料

  • SK Biopharmaceuticals Co., Ltd.概要
  • 主要資訊
  • 企業資料

SK Biopharmaceuticals Co., Ltd.:R&D概要

  • 主要的治療範圍

SK Biopharmaceuticals Co., Ltd.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

SK Biopharmaceuticals Co., Ltd.:開發中產品概況

  • 最後階段的開發中產品
    • 第Ⅲ階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第Ⅱ階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在IND/CTA 申請的產品/聯合治療模式
    • 在前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

SK Biopharmaceuticals Co., Ltd.:藥物簡介

  • SKL-N05
  • YKP-3089
  • relenopride hydrochloride
  • carisbamate
  • SKL-15508
  • SKL-A4R
  • SKL-PD
  • SKL-PSY
  • N-2
  • SKL-16036
  • SKL-G
  • 多發性硬化症治療用小分子
  • 神經性疼痛治療用小分子
  • Tauopathies,老年癡呆症治療用小分子
  • 肌肉萎縮性側索硬化症用 TDP-43 阻礙小分子

SK Biopharmaceuticals Co., Ltd.:開發平台分析

  • 各標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

SK Biopharmaceuticals Co., Ltd.:最近的開發平台趨勢

SK Biopharmaceuticals Co., Ltd.:暫停中的計劃

SK Biopharmaceuticals Co., Ltd.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • carisbamate

SK Biopharmaceuticals Co., Ltd.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08018CDB

Summary

Global Markets Direct's, 'SK Biopharmaceuticals Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the SK Biopharmaceuticals Co., Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by SK Biopharmaceuticals Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of SK Biopharmaceuticals Co., Ltd.
  • The report provides overview of SK Biopharmaceuticals Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses SK Biopharmaceuticals Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features SK Biopharmaceuticals Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate SK Biopharmaceuticals Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for SK Biopharmaceuticals Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding SK Biopharmaceuticals Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • SK Biopharmaceuticals Co., Ltd. Snapshot
    • SK Biopharmaceuticals Co., Ltd. Overview
    • Key Information
    • Key Facts
  • SK Biopharmaceuticals Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • SK Biopharmaceuticals Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • SK Biopharmaceuticals Co., Ltd. - Pipeline Products Glance
    • SK Biopharmaceuticals Co., Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • SK Biopharmaceuticals Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • SK Biopharmaceuticals Co., Ltd. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • SK Biopharmaceuticals Co., Ltd. - Drug Profiles
    • SKL-N05
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YKP-3089
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • relenopride hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • carisbamate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SKL-15508
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SKL-A4R
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SKL-PD
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SKL-PSY
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • N-2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SKL-16036
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SKL-DEP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SKL-G
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Multiple Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Neuropathic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Tauopathies and Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • SK Biopharmaceuticals Co., Ltd. - Pipeline Analysis
    • SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Target
    • SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Route of Administration
    • SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Molecule Type
    • SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Mechanism of Action
  • SK Biopharmaceuticals Co., Ltd. - Recent Pipeline Updates
  • SK Biopharmaceuticals Co., Ltd. - Dormant Projects
  • SK Biopharmaceuticals Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • carisbamate
  • SK Biopharmaceuticals Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • SK Biopharmaceuticals Co., Ltd., Key Information
  • SK Biopharmaceuticals Co., Ltd., Key Facts
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Indication, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Stage of Development, 2016
  • SK Biopharmaceuticals Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • SK Biopharmaceuticals Co., Ltd. - Phase III, 2016
  • SK Biopharmaceuticals Co., Ltd. - Phase II, 2016
  • SK Biopharmaceuticals Co., Ltd. - Phase I, 2016
  • SK Biopharmaceuticals Co., Ltd. - IND/CTA Filed, 2016
  • SK Biopharmaceuticals Co., Ltd. - Preclinical, 2016
  • SK Biopharmaceuticals Co., Ltd. - Discovery, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Target, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Route of Administration, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Molecule Type, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
  • SK Biopharmaceuticals Co., Ltd. - Recent Pipeline Updates, 2016
  • SK Biopharmaceuticals Co., Ltd. - Dormant Developmental Projects,2016
  • SK Biopharmaceuticals Co., Ltd. - Discontinued Pipeline Products, 2016
  • SK Biopharmaceuticals Co., Ltd., Other Locations
  • SK Biopharmaceuticals Co., Ltd., Subsidiaries

List of Figures

  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Top 10 Indication, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Stage of Development, 2016
  • SK Biopharmaceuticals Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Top 10 Target, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Route of Administration, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Molecule Type, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top